486 related articles for article (PubMed ID: 19699450)
1. [Update on the second line management of idiopathic overactive bladder].
Chartier-Kastler E; Castro-Diaz D; De Ridder D; Everaert K; Sievert KD; Spinelli M; van Kerrebroeck P
Prog Urol; 2009 Sep; 19(8):530-7. PubMed ID: 19699450
[TBL] [Abstract][Full Text] [Related]
2. Current information on sacral neuromodulation and botulinum toxin treatment for refractory idiopathic overactive bladder syndrome: a review.
Leong RK; De Wachter SG; van Kerrebroeck PE
Urol Int; 2010; 84(3):245-53. PubMed ID: 20389150
[TBL] [Abstract][Full Text] [Related]
3. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
[TBL] [Abstract][Full Text] [Related]
4. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice?
Chapple C; De Ridder D
BJU Int; 2009 Nov; 104(9):1188-90. PubMed ID: 19681899
[No Abstract] [Full Text] [Related]
5. [Neuromodulation as a treatment for overactive bladder syndrome].
Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
[TBL] [Abstract][Full Text] [Related]
6. An overview of treatment of overactive bladder syndrome in women.
Allahdin S; Oo N
J Obstet Gynaecol; 2012 Apr; 32(3):217-21. PubMed ID: 22369391
[TBL] [Abstract][Full Text] [Related]
7. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
8. Treatment of overactive bladder symptoms beyond antimuscarinics: current and future therapies.
Ellsworth P
Postgrad Med; 2012 May; 124(3):16-27. PubMed ID: 22691895
[TBL] [Abstract][Full Text] [Related]
9. Overactive bladder syndrome - management and treatment options.
Arnold J; McLeod N; Thani-Gasalam R; Rashid P
Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
[TBL] [Abstract][Full Text] [Related]
10. [Guidelines for treatment of urinary incontinence in women due to refractory idiopathic vesical hyperactivity with botulinum toxin A].
Peyrat L; Ragni E;
Prog Urol; 2010 Feb; 20 Suppl 2():S170-3. PubMed ID: 20403570
[TBL] [Abstract][Full Text] [Related]
11. Overactive Bladder.
White N; Iglesia CB
Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation and intravesical botulinum toxin for refractory overactive bladder.
Kantartzis K; Shepherd J
Curr Opin Obstet Gynecol; 2012 Oct; 24(5):331-6. PubMed ID: 22922403
[TBL] [Abstract][Full Text] [Related]
13. What treatment should we use if drugs fail for OAB; and, what really works after drugs?
Bosch JL; Kelleher C; van Kerrebroeck PE; Schurch B
Neurourol Urodyn; 2010 Apr; 29(4):658-61. PubMed ID: 20432331
[TBL] [Abstract][Full Text] [Related]
14. Overactive bladder--a practical approach to evaluation and management.
Madersbacher H
J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
[TBL] [Abstract][Full Text] [Related]
15. Sacral neuromodulation and refractory overactive bladder: an emerging tool for an old problem.
Banakhar MA; Al-Shaiji T; Hassouna M
Ther Adv Urol; 2012 Aug; 4(4):179-85. PubMed ID: 22852028
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin in the treatment of OAB, BPH, and IC.
Smith CP
Toxicon; 2009 Oct; 54(5):639-46. PubMed ID: 19268490
[TBL] [Abstract][Full Text] [Related]
17. Novel uses for antidiuresis.
Hashim H; Abrams P
Int J Clin Pract Suppl; 2007 Sep; (155):32-6. PubMed ID: 17727577
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
[TBL] [Abstract][Full Text] [Related]
19. Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units.
Cohen BL; Barboglio P; Rodriguez D; Gousse AE
Neurourol Urodyn; 2009; 28(3):205-8. PubMed ID: 19058190
[TBL] [Abstract][Full Text] [Related]
20. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
